Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

The SARS-CoV-2 Delta variant is believed to spread faster than other variants. The Delta variant was resistant to neutralization by some monoclonal antibodies targeting N-terminal domain or receptor-binding domain of spike protein, such as Bamlanivimab. Sera from convalescent patients and Pfizer or AstraZeneca vaccinated individuals showed reduced potency to neutralize the Delta variant.